➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Baxter
Merck
Johnson and Johnson
AstraZeneca

Last Updated: August 6, 2020

DrugPatentWatch Database Preview

FUROSEMIDE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Furosemide patents expire, and what generic alternatives are available?

Furosemide is a drug marketed by Abraxis Pharm, Accord Hlthcare, Am Regent, Amneal Pharms Co, Astrazeneca, Aurobindo Pharma Ltd, Baxter Hlthcare Corp, Emcure Pharms Ltd, Fresenius Kabi Usa, Hospira, Igi Labs Inc, Intl Medication, Marsam Pharms Llc, Smith And Nephew, Warner Chilcott, Watson Labs, West-ward Pharms Int, Wockhardt, Wyeth Ayerst, Hikma, Wockhardt Bio Ag, Ani Pharms Inc, Avet, Dava Pharms Inc, Ipca Labs Ltd, Kalapharm, Leading Pharma Llc, Mylan, Prinston Inc, Sandoz, Sun Pharm Inds Inc, Sun Pharm Industries, Superpharm, and Watson Labs Teva. and is included in fifty-eight NDAs.

The generic ingredient in FUROSEMIDE is furosemide. There are twenty-two drug master file entries for this compound. Forty-five suppliers are listed for this compound. Additional details are available on the furosemide profile page.

US ANDA Litigation and Generic Entry Outlook for Furosemide

A generic version of FUROSEMIDE was approved as furosemide by SANDOZ on August 14th, 1984.

  Start Trial

Drug patent expirations by year for FUROSEMIDE
Drug Prices for FUROSEMIDE

See drug prices for FUROSEMIDE

Drug Sales Revenue Trends for FUROSEMIDE

See drug sales revenues for FUROSEMIDE

Recent Clinical Trials for FUROSEMIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Otsuka Pharmaceutical VietnamN/A
Gia Dinh People HospitalN/A
Assiut UniversityPhase 4

See all FUROSEMIDE clinical trials

Pharmacology for FUROSEMIDE
Medical Subject Heading (MeSH) Categories for FUROSEMIDE

US Patents and Regulatory Information for FUROSEMIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Warner Chilcott FUROSEMIDE furosemide TABLET;ORAL 018419-002 Jan 31, 1983 DISCN No No   Start Trial   Start Trial   Start Trial
Hikma FUROSEMIDE furosemide TABLET;ORAL 018823-002 Nov 10, 1983 AB RX No No   Start Trial   Start Trial   Start Trial
Ani Pharms Inc FUROSEMIDE furosemide TABLET;ORAL 071379-001 Jan 2, 1987 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Merck
Colorcon
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.